FDA Approves Allergan's sNDA for AVYCAZ(r) (ceftazidime and avibactam) to include new Phase III data in Patients with Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis

Source :: Plus Company Updates. February 3, 2017
Publication Year :: 2017
Abstract: DUBLIN: Allergan plc has issued the following news release: Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved the [...]

Subjects :: United States. Food and Drug Administration
Allergan PLC -- Product development
Pyelonephritis
Urinary tract infections
Pharmaceutical industry -- Product development
Drug approval
General interest
News, opinion and commentary
Avycaz (Medication)

Tools